PEERLESS II 研究
ピアレス II: 肺塞栓症におけるフロートリーバーと抗凝固療法単独の RCT
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35243
- Brookwood Medical Center
-
Birmingham、Alabama、アメリカ、35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena、California、アメリカ、91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
-
Florida
-
Largo、Florida、アメリカ、33770
- HCA FL Largo Medical Center
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
-
Michigan
-
Lansing、Michigan、アメリカ、48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital of Kansas City
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Virtua Health
-
-
New York
-
Buffalo、New York、アメリカ、14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York、New York、アメリカ、10075
- Northwell Health
-
Rochester、New York、アメリカ、14642
- University of Rochester Medical Center
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Hospital
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Medical Center
-
Cleveland、Ohio、アメリカ、44195
- The Cleveland Clinic Foundation
-
Columbus、Ohio、アメリカ、43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、アメリカ、18015
- St. Luke's University Hospital
-
Erie、Pennsylvania、アメリカ、16507
- UPMC Hamot
-
Erie、Pennsylvania、アメリカ、16505
- AHN Saint Vincent Hospital
-
Harrisburg、Pennsylvania、アメリカ、17101
- UPMC Harrisburg
-
Philadelphia、Pennsylvania、アメリカ、19144
- Thomas Jefferson University
-
Philadelphia、Pennsylvania、アメリカ、19104
- The University of Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- UPMC Heart and Vascular Institute
-
Pittsburgh、Pennsylvania、アメリカ、15212
- Allegheny Health Network Research Institute
-
York、Pennsylvania、アメリカ、17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood、Tennessee、アメリカ、37027
- HCA Tristar
-
Knoxville、Tennessee、アメリカ、37920
- UTMC Knoxville
-
Nashville、Tennessee、アメリカ、37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Parkland Hospital
-
Fort Worth、Texas、アメリカ、76104
- Texas Health Harris Methodist Hospital
-
San Antonio、Texas、アメリカ、78229
- Methodist Main Hospital
-
Temple、Texas、アメリカ、76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- Inova Fairfax
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Charleston Area Medical Center
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
-
-
-
British Columbia
-
New Westminster、British Columbia、カナダ、V3L 3W7
- Royal Columbian Hospital
-
Surrey、British Columbia、カナダ、V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver、British Columbia、カナダ、V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Basel、スイス
- Universitaetsspital Basel
-
Bern、スイス
- Universitätsspital Bern
-
Lucerne、スイス
- Luzerner Kantonsspital
-
-
-
-
-
Madrid、スペイン
- Hopital Clinico Universitario San Carlos
-
-
-
-
-
Aarhus、デンマーク、8200
- Aarhus University Hospital
-
-
-
-
-
Augsburg、ドイツ
- University Hospital Augsburg
-
Bad Krozingen、ドイツ
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin、ドイツ
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin、ドイツ
- Unfall Krankenhaus Berlin
-
Cologne、ドイツ
- University Hospital Cologne
-
Dresden、ドイツ
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf、ドイツ
- Universitaetsklinikum Dὒsseldorf
-
Essen、ドイツ
- Universitaetsklinikum Essen
-
Essen、ドイツ
- Elisabeth Hospital GmbH
-
Frankfurt、ドイツ
- CCB Frankfurt
-
Hamburg、ドイツ
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg、ドイツ
- University Hospital - Heidelberg
-
Kaiserslautern、ドイツ
- Westpfalz Klinikum
-
Munich、ドイツ
- Klinikum rechts der Isar (TUM)
-
Munich、ドイツ
- Ludwig Maximilians-University
-
Regensburg、ドイツ
- University Hospital Regensburg
-
Villingen-Schwenningen、ドイツ
- Schwarzwald-Baar-Klinikum
-
-
-
-
-
Lille、フランス
- CHU Lille
-
Lyon、フランス
- Hôpital Louis Pradel
-
Marseille、フランス
- Hôpital Nord Marseille
-
Marseille、フランス
- AP-HM Hopital La Timone
-
-
-
-
-
Aalst、ベルギー
- Onze Lieve Vrouwziekenhuis
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
アクティブコンパレータ:Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
時間枠:through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
全死因死亡率とPE関連死亡率
時間枠:30日と90日の時点
|
30日と90日の時点
|
|
|
全原因およびPE関連の再入院
時間枠:30日と90日の時点
|
30日と90日の時点
|
|
|
徒歩6分
時間枠:1ヶ月ぶりの訪問時
|
1ヶ月ぶりの訪問時
|
|
|
RV/LV比
時間枠:48時間の訪問時
|
48時間の訪問時
|
|
|
PE 後の障害診断 (PPEI)
時間枠:3ヶ月間の訪問を通じて
|
3ヶ月間の訪問を通じて
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
時間枠:up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
時間枠:Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
時間枠:Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
時間枠:At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
時間枠:At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
時間枠:At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
時間枠:At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Jay Giri, MD、Penn Medicine
- 主任研究者:Bernhard Gebauer, MD、Charité University Hospital Berlin
- 主任研究者:Felix Mahfoud, MD、Universitaetsspital Basel
- 主任研究者:Frances Mae West, MD、Jefferson Health
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。